Theravance Biopharma (TBPH) FCF Margin (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly FCF Margin of 414.03% for Q1 2026, up 13434.0% year-over-year from N/an in Q1 2025, and up 3229.15% quarter-over-quarter from 13.23% in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) FCF Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported FCF Margin for 14 consecutive years, with 414.03% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 13434.0% year-over-year to 414.03%; the TTM figure through Mar 2026 stood at 244.84% (up 19537.0% YoY), while the FY2025 annual figure was 3179.99%, up 319842.0% from the prior year.
- FCF Margin advanced to 414.03% in Q1 2026 per TBPH's latest filing, from 13.23% in the prior quarter.
- Across five years, FCF Margin topped out at 794.33% in Q2 2025 and bottomed at 199.45% in Q1 2022.
- Historically, FCF Margin has averaged 60.91% across 5 years, with a median of 15.98% in 2023.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 38176 bps — and 2025, when it jumped 82555 bps.
- Theravance Biopharma's FCF Margin stood at 373.04% in 2022, then plunged by 102 bps to 8.72% in 2023, then soared by 33 bps to 5.82% in 2024, then plunged by 127 bps to 13.23% in 2025, then jumped by 3229 bps to 414.03% in 2026.
- Business Quant data shows TBPH's FCF Margin at 414.03% in Q1 2026, 13.23% in Q4 2025, and 32.56% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -33.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33.60% |
| Mar 31, 2026 | 414.03% |
| Dec 31, 2025 | -13.23% |
| Sep 30, 2025 | -32.56% |
| Jun 30, 2025 | 794.33% |
| Mar 31, 2025 | 279.69% |
| Dec 31, 2024 | -5.82% |
| Sep 30, 2024 | -30.89% |
| Jun 30, 2024 | -31.22% |
| Mar 31, 2024 | -7.67% |
| Dec 31, 2023 | -8.72% |
| Sep 30, 2023 | -15.98% |
| Jun 30, 2023 | -96.65% |
| Mar 31, 2023 | -116.72% |
| Dec 31, 2022 | -848.67% |
| Sep 30, 2022 | -177.34% |
| Jun 30, 2022 | -128.76% |
| Mar 31, 2022 | -204.11% |
| Dec 31, 2021 | -305.73% |
| Sep 30, 2021 | -542.56% |